Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Nuvation Bio (NUVB) and Argenx Se (ARGX)

Tipranks - Tipranks - Fri Apr 3, 7:30AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA), Nuvation Bio (NUVB) and Argenx Se (ARGX) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Teva Pharmaceutical (TEVA)

Goldman Sachs analyst Salveen Richter maintained a Buy rating on Teva Pharmaceutical yesterday and set a price target of $45.00. The company’s shares closed last Wednesday at $30.25.

According to TipRanks.com, Richter is a 5-star analyst with an average return of 10.8% and a 46.8% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, 4D Molecular Therapeutics, and Vertex Pharmaceuticals. ;'>

Teva Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $39.44, which is a 29.4% upside from current levels. In a report issued on March 17, TipRanks – PerPlexity also upgraded the stock to Buy with a $32.00 price target.

See the top stocks recommended by analysts >>

Nuvation Bio (NUVB)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Nuvation Bio, with a price target of $11.00. The company’s shares closed last Wednesday at $4.51.

According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 15.3% and a 48.3% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Perspective Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Nuvation Bio has an analyst consensus of Strong Buy, with a price target consensus of $12.00, a 174.0% upside from current levels. In a report released today, Truist Financial also maintained a Buy rating on the stock.

Argenx Se (ARGX)

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Argenx Se, with a price target of $1014.00. The company’s shares closed last Wednesday at $743.12.

According to TipRanks.com, Gershell is a 4-star analyst with an average return of 4.3% and a 39.5% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Crinetics Pharmaceuticals, and Lexeo Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $1033.29 average price target, which is a 39.4% upside from current levels. In a report issued on March 18, Wedbush also maintained a Buy rating on the stock with a $1000.00 price target.

Read More on TEVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).